Cutaneous Melanoma by AJCC V7 Stage Clinical Trial
— MelMarTOfficial title:
A Phase III, Multi-centre, Multi-national Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma
| Verified date | April 2022 |
| Source | Melanoma and Skin Cancer Trials Limited |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with a primary invasive cutaneous melanomas >=1mm thick to determine differences in the rate of local recurrence and melanoma specific survival. A reduction in margins is expected to improve quality of life in patients
| Status | Active, not recruiting |
| Enrollment | 400 |
| Est. completion date | August 5, 2026 |
| Est. primary completion date | August 4, 2016 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: 1. Patients must have a primary invasive cutaneous melanoma of Breslow thickness greater than 1 millimetre as determined by diagnostic biopsy (narrow excision, incision or punch biopsy) and subsequent histopathological analysis. 2. Patients must have had the invasive primary completely excised, including any in situ component but excluding melanocytic atypia, with a narrow margin, either in one stage or more than one stage in the case where an incision or punch biopsy has previously been performed. This information, including measured margins of lateral and deep clearance must be documented on the pathology report. 3. Must have a primary melanoma that is cutaneous (including head, neck, trunk, extremity, scalp, palm, sole). 4. An uninterrupted 2cm margin must be technically feasible around biopsy scar or primary melanoma. 5. Randomisation and the primary study intervention, including staging sentinel node biopsy, must be completed by 120 days of original diagnosis. 6. Patients must be 18 years or older at time of consent. 7. Patient must be able to give informed consent and comply with the treatment protocol and follow-up plan. 8. Life expectancy of at least 10 years from the time of diagnosis, not considering the melanoma in question, as determined by the PI. 9. Patients must have an ECOG performance score between 0 and 1. 10. A survivor of prior cancer is eligible provided that ALL of the following criteria are met and documented: - The patient has undergone potentially curative therapy for all prior malignancies, - There has been no evidence of recurrence of any prior malignancies for at least FIVE years (except for successfully treated cervical or non-melanoma skin cancer with no evidence of recurrence), and - The patient is deemed by their treating physician to be at low risk of recurrence from previous malignancies. Exclusion Criteria: 1. Uncertain diagnosis of melanoma i.e. so-called 'melanocytic lesion of unknown malignant potential'. 2. Patient has already undergone wide local excision at the site of the primary index lesion. 3. Patient unable or ineligible to undergo staging sentinel lymph node biopsy of the primary index lesion. 4. Desmoplastic or neurotropic melanoma. 5. Microsatellitosis as per AJCC 2009 definition 6. Subungual melanoma 7. Patient has already undergone a local flap reconstruction of the defect after excision of the primary and determination of an accurate excision margin is impossible. 8. History of previous or concurrent (i.e., second primary) invasive melanoma. 9. Melanoma located distal to the metacarpophalangeal joint, on the tip of the nose, the eyelids or on the ear, mucous membranes or internal viscera. 10. Physical, clinical, radiographic or pathologic evidence of satellite, in-transit, regional, or distant metastatic melanoma. 11. Patient has undergone surgery on a separate occasion to clear the lymph nodes of the probable draining lymphatic field, including sentinel lymph node biopsy, of the index melanoma. 12. Any additional solid tumour or hematologic malignancy during the past 5 years except T1 skin lesions of squamous cell carcinoma, basal cell carcinoma, or uterine/cervical cancer. 13. Melanoma-related operative procedures not corresponding to criteria described in the protocol. 14. Planned adjuvant radiotherapy to the primary melanoma site after Wide Local Excision is not permitted as part of the protocol and any patients given this treatment would be excluded from the study. 15. History of organ transplantation. 16. Oral or parenteral immunosuppressive agents (not topical or inhaled steroids) at any time during study participation or within 6 months prior to enrolment. |
| Country | Name | City | State |
|---|---|---|---|
| Australia | Gold Coast Melanom Clinic | Coolangatta | Queensland |
| Australia | Alfred Hospital | Melbourne | Victoria |
| Australia | Peter MacCallum Cancer Centre Division of Cancer Surgery | Melbourne | Victoria |
| Australia | Melanoma Institute Australia - Poche Centre | North Sydney | New South Wales |
| Canada | Sunnybrook Health Sciences Centre | Toronto | |
| Sweden | Sahlgrenska University Hospital | Göteborg | |
| United Kingdom | North Bristol NHS Trust | Bristol | |
| United Kingdom | Mid Essex Hospital Services NHS Trust | Broomfield | Essex |
| United Kingdom | Cambridge University Hospitals NHS Foundation Trust | Cambridge | |
| United Kingdom | Royal Devon and Exeter NHS Foundation Trust | Exeter | |
| United Kingdom | Oxford University Hospitals NHS Trust | Headington | Oxford |
| United Kingdom | Hull and East Yorkshire Hospitals NHS Trust | Hull | England |
| United Kingdom | St. James University Hospital | Leeds | |
| United Kingdom | Guy's and St Thomas' Hospital NHS Trust | London | England |
| United Kingdom | Imperial College Healthcare NHS Trust | London | |
| United Kingdom | Royal Free London NHS Foundation Trust | London | |
| United Kingdom | The Christie NHS Foundation Trust | Manchester | England |
| United Kingdom | Norfolk and Norwich University Hospital | Norwich | |
| United Kingdom | St Helens & Knowsley NHS Trust | St Helens | Mersyside |
| United States | Thomas Jefferson University Hospital | Philadelphia | Pennsylvania |
| Lead Sponsor | Collaborator |
|---|---|
| Melanoma and Skin Cancer Trials Limited | Norfolk and Norwich University Hospitals NHS Foundation Trust, Peter MacCallum Cancer Centre, Australia |
United States, Australia, Canada, Sweden, United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Local Melanoma Recurrence (Melanoma Specific Survival) | Time from randomisation to clinically, histologically or radiologically confirmed local recurrence of melanoma including satellite lesions and in transit metastases to regional draining lymph nodes. | 0-120 months | |
| Secondary | Recurrence-Free Survival | Time from randomisation to any clinical, histological or radiologically confirmed melanoma recurrence or death from any cause. | 0-120 months | |
| Secondary | QoL and neuropathic pain assessments Neuropathic Pain (PainDetect) | Quality of Life | Baseline, 3, 6 12, 24 & 60 months. | |
| Secondary | Overall Survival | Time from randomisation to death from any cause. | 0-120 Months | |
| Secondary | Adverse events | An Adverse Event (AE) is any untoward medical occurrence in a participant administered a treatment which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavourable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the treatment timing, whether or not considered related to the treatment. An AE is any adverse change (developing or worsening) from the participant's pre-treatment condition, including intercurrent illness.
AEs and any pre-existing medical conditions will be recorded at the Baseline assessment and routinely at Follow Up, until the participant completes the study, withdraws or dies. |
Within 1 year | |
| Secondary | Surgery related adverse events | The following surgical adverse events will be recorded from the time of trial treatment to 30 days following the wide excision (inclusive):
wound separation seroma/haematoma at wide local excision site haemorrhage infection skin graft failure necrosis of flap used for reconstruction deep venous thrombosis urinary tract infection pneumonia cardiac complications |
Up to 30 days from randomisation | |
| Secondary | Health System Resource Use | All hospitalisations and other interventions will be captured in order to measure resource use. | Baseline, 3, 6, 12, 24 and 60 months |